Rebecca Cook
Faculty Member
Last active: 4/15/2019

  1. Rictor/mTORC2 Drives Progression and Therapeutic Resistance of HER2-Amplified Breast Cancers. Morrison Joly M, Hicks DJ, Jones B, Sanchez V, Estrada MV, Young C, Williams M, Rexer BN, Sarbassov dos D, Muller WJ, Brantley-Sieders D, Cook RS (2016) Cancer Res 76(16): 4752-64
    › Primary publication · 27197158 (PubMed) · PMC5758362 (PubMed Central)
  2. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM (2016) Clin Cancer Res 22(6): 1499-509
    › Primary publication · 26515496 (PubMed) · PMC4794351 (PubMed Central)
  3. Mouse Models of Breast Cancer: Platforms for Discovering Precision Imaging Diagnostics and Future Cancer Medicine. Manning HC, Buck JR, Cook RS (2016) J Nucl Med : 60S-8S
    › Primary publication · 26834104 (PubMed) · PMC6231414 (PubMed Central)
  4. Drug response in organoids generated from frozen primary tumor tissues. Walsh AJ, Cook RS, Sanders ME, Arteaga CL, Skala MC (2016) Sci Rep : 18889
    › Primary publication · 26738962 (PubMed) · PMC4703961 (PubMed Central)
  5. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS (2016) Oncogene 35(9): 1206
    › Primary publication · 26935538 (PubMed)
  6. Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth. Morrison MM, Williams MM, Vaught DB, Hicks D, Lim J, McKernan C, Aurisicchio L, Ciliberto G, Simion C, Sweeney C, Cook RS (2016) Oncogene 35(9): 1143-52
    › Primary publication · 26148232 (PubMed) · PMC4703573 (PubMed Central)
  7. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells. Canfield K, Li J, Wilkins OM, Morrison MM, Ung M, Wells W, Williams CR, Liby KT, Vullhorst D, Buonanno A, Hu H, Schiff R, Cook RS, Kurokawa M (2015) Cell Cycle 14(4): 648-55
    › Primary publication · 25590338 (PubMed) · PMC4614407 (PubMed Central)
  8. mTOR Directs Breast Morphogenesis through the PKC-alpha-Rac1 Signaling Axis. Morrison MM, Young CD, Wang S, Sobolik T, Sanchez VM, Hicks DJ, Cook RS, Brantley-Sieders DM (2015) PLoS Genet 11(7): e1005291
    › Primary publication · 26132202 (PubMed) · PMC4488502 (PubMed Central)
  9. Efferocytosis creates a tumor microenvironment supportive of tumor survival and metastasis. Vaught DB, Stanford JC, Cook RS (2015) Cancer Cell Microenviron 2(1)
    › Primary publication · 29264372 (PubMed) · PMC5734109 (PubMed Central)
  10. Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. Young CD, Arteaga CL, Cook RS (2015) Breast Cancer Res : 148
    › Primary publication · 26637440 (PubMed) · PMC4670529 (PubMed Central)